Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
Reyna K, Heinzen G, Patel N, Ritter M, Siojo A, Legere H, et al.
Published in Front Aging, Vol. 7, pp. 1652582
Methodology
Retrospective review of medical records from a commercial clinic: clients received 500 mg NAD+ IV or 500 mg nicotinamide riboside (NR) IV on four consecutive days, with 30 days of follow-up. Outcomes were symptoms, infusion time, vital signs and safety and metabolic blood markers.
Key Findings
NAD+ IV caused moderate to severe gastrointestinal symptoms, increased heart rate and chest pressure during infusions; NR IV caused minor tingling and mild cramping. All symptoms resolved when the infusion ended. Infusions averaged 97 minutes for NAD+ versus 37 minutes for NR. Liver, kidney, thyroid and hsCRP markers did not change; HDL-C fell with NAD+ IV and HbA1c fell with NR IV.
Conclusions
Preliminary real-world evidence on tolerability and short-term safety; metabolic effects were variable and need further study.
Limitations
Retrospective, non-randomised and unblinded; commercial setting; group sizes not given in the abstract; 30-day follow-up.
Supplements Studied
NAD+ IV reported moderate to severe gastrointestinal symptoms
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.